Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL positive |
| Therapy | Enapotamab vedotin |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | Advanced Solid Tumor | predicted - sensitive | Enapotamab vedotin | Preclinical - Pdx | Actionable | In a preclinical study, Enapotamab vedotin (HuMax-Axl-ADC) inhibited tumor growth in solid tumor xenograft models, including induction of tumor regression in solid tumor patient-derived xenograft (PDX) models expressing Axl in a subset of tumor cells (J Clin Onc 2015 33:15_suppl, 3066). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers. | Full reference... |